Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2015

01-08-2015 | Erratum

Erratum to: Anti-miR-362-3p Inhibits Migration and Invasion of Human Gastric Cancer Cells by Its Target CD82

Authors: Qing-Hui Zhang, Yong-Liang Yao, Xiao-Yang Wu, Jian-Hong Wu, Tao Gu, Ling Chen, Jin-Hua Gu, Yun Liu, Ling Xu

Published in: Digestive Diseases and Sciences | Issue 8/2015

Login to get access

Excerpt

The original version of this article unfortunately contained an error in “Abstract.” An entry in the “Result” section of the abstract should be changed to “induced” instead of “inhibited.” …
Metadata
Title
Erratum to: Anti-miR-362-3p Inhibits Migration and Invasion of Human Gastric Cancer Cells by Its Target CD82
Authors
Qing-Hui Zhang
Yong-Liang Yao
Xiao-Yang Wu
Jian-Hong Wu
Tao Gu
Ling Chen
Jin-Hua Gu
Yun Liu
Ling Xu
Publication date
01-08-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3605-0

Other articles of this Issue 8/2015

Digestive Diseases and Sciences 8/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine